Appropriate Dosing of Bendamustine for Lymphodepletion prior to CAR T-Cell Therapy
In patients undergoing chimeric antigen receptor (CAR) T-cell therapy for indications such as diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma (FL), bendamustine can be used as part of lymphodepleting chemotherapy particularly when cyclophosphamide is contraindicated or the patient exhibits chemorefractoriness to cyclophosphamide-containing regimens. The recommended bendamustine dosing for lymphodepletion in this context is 90 mg/mSmPC Bendamustine administered intravenously once daily for 2 days SmPC Kymriah.
This dosing schedule is intended to replace standard lymphodepleting regimens based on fludarabine and cyclophosphamide, notably in patients who have experienced prior grade 4 hemorrhagic cystitis with cyclophosphamide or demonstrated chemoresistance to cyclophosphamide-containing regimens shortly before lymphodepleting chemotherapy SmPC Kymriah.
The administration of bendamustine should be performed via intravenous infusion over 30 to 60 minutes under supervision by a qualified physician experienced in chemotherapy delivery SmPC Bendamustine,SmPC Bendamustine. These recommendations reflect current UK prescribing information for lymphodepleting chemotherapy preceding CAR T-cell infusion (e.g., Kymriah) SmPC Kymriah.
While bendamustine is commonly dosed at 100–120 mg/mSmPC Bendamustine on days 1 and 2 for therapeutic indications such as chronic lymphocytic leukemia or indolent non-Hodgkin’s lymphoma SmPC Bendamustine,SmPC Bendamustine, the lymphodepleting dose specifically for CAR T-cell therapy lymphodepletion is lower at 90 mg/mSmPC Bendamustine daily for 2 days, reflecting a regimen focused on transient immunosuppression and lymphodepletion rather than direct anti-lymphoma cytotoxicity SmPC Kymriah.
Fludarabine combined with cyclophosphamide remains the standard lymphodepleting backbone for CAR T-cell therapy in many lymphomas, with bendamustine reserved for specific cases as above; typical fludarabine dosing is 25 mg/mSmPC Bendamustine to 30 mg/mSmPC Bendamustine intravenously daily for 3–4 days with cyclophosphamide at 250–500 mg/mSmPC Bendamustine daily for 2–3 days SmPC Kymriah.
From published clinical experiences and emerging literature in CAR T-cell therapy, lymphodepletion with fludarabine and cyclophosphamide has been shown to create an immunomodulatory milieu conducive to CAR T-cell expansion and persistence, but bendamustine-based lymphodepletion is recognized as an alternative when indicated to minimize toxicity related to cyclophosphamide SmPC Kymriah Caserta et al. 2026.
Overall, the use of bendamustine at 90 mg/mSmPC Bendamustine IV daily for 2 days for lymphodepletion is appropriate in patients with contraindications to fludarabine-cyclophosphamide lymphodepletion or prior severe cyclophosphamide toxicity and is consistent with UK regulatory guidance and internationally recognized best practice standards SmPC Kymriah,SmPC Bendamustine,SmPC Bendamustine.
Key References
- SmPC: Kymriah cells dispersion for infusion
- SmPC: Bendamustine hydrochloride 2.5mg/ml Powder
- SmPC: Bendamustine Hydrochloride 2.5mg/ml powder for concentrate for solution for infusion
- NICE NG52: Non-Hodgkin's lymphoma: diagnosis and management
- (Caserta et al., 2026): T-Cell-Redirecting Immunotherapies in Relapsed/Refractory Mantle Cell Lymphoma: Current Evidence, Sequencing, and Future Directions.
- (Synnott et al., 2026): Systematic Review of Immunosuppression After Chimeric Antigen Receptor T-Cell Therapy for Posttransplant Lymphoproliferative Disorder.
- (Mayasin et al., 2026): Put the CAR-T before the HRS: Advances in Anti-CD30 Immunotherapy Targeting Hodgkin/Reed-Sternberg Cells in Classical Hodgkin Lymphoma.